Skip to main content
×
Home
    • Aa
    • Aa

Pharmacokinetics and pharmacodinamics of psychotropic drugs: effect of sex

Abstract

Data on the specific effects of sex on pharmacokinetics, as well as tolerability, safety, and efficacy of psychotropic medications are still meager, mainly because only recently sex-related issues have attracted a certain degree of interest within the pharmacological domain. Therefore, with the present study, we aimed to provide a comprehensive review of the literature on this topic, through careful MEDLINE and PubMed searches of the years 1990–2012.

Generally, data on pharmacokinetics are more consistent and numerous than those on pharmacodynamics. Sex-related differences have been reported for several parameters that influence pharmacokinetics, such as gastric acidity, intestinal motility, body weight and composition, blood volume, liver enzymes (mainly the cytochrome P450), or renal excretion, which may alter plasma drug levels. Sex-related peculiarities may also account for a different sensitivity of men and women to side effects and toxicity of psychotropic drugs. Further, some differences in drug response, mainly to antipsychotics and antidepressants, have been described.

Further studies are, however, necessary to explore more thoroughly the impact of sex on the pharmacokinetics and pharmacodynamics of psychotropic drugs, in order to reach the most appropriate and tailored prescription for each patient.

Copyright
Corresponding author
*Address for correspondence: Donatella Marazziti, MD, Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie, University of Pisa, Via Roma 67, 56100 Pisa, Italy. (Email dmarazzi@psico.med.unipi.it)
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

2. M Frezza , C di Padova , G Pozzato , etal. High blood alcohol levels in women: the role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med. 1990; 322: 9599.

4. S Rao , N Read , C Brown , etal. Studies on the mechanism of bowel disturbance in ulcerative colitis. Gastroenterology. 1987; 93: 934940.

7. JM Nicolas , P Espie , M Molimard . Gender and interindividual variability in pharmacokinetics. Drug Metab Rev. 2009; 41(3): 408421.

8. ML Chen , SC Lee , MJ Ng , etal. Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin Pharmacol Ther. 2000; 68(5): 510521.

12. R Sweet , B Pollock , B Wright , etal. Single and multiple dose bupropion pharmacokinetics in elderly patients with depression. J Clin Pharmacol. 1995; 35: 876884.

13. SL Brown , ME Salive , JM Guralnik , etal. Antidepressant use in the elderly: association with demographic characteristics, health-related factors, and health care utilization. J Clin Epidemiol. 1995; 48: 445453.

14. L Simoni Wastila . Gender and psychotropic drug use. Med Care. 1998; 36: 8894.

15. CH Gleiter , U Gundert-Remy . Gender differences in pharmacokinetics. Eur J Drug Metab Pharmacokinet. 1996; 21: 123128.

16. S Hashimoto , M Miwa , K Akasofu , E Nishida . Changes in 40 serum proteins of post-menopausal women. Maturitas. 1991; 13: 2333.

17. PG Blain , JC Mucklow , MD Rawlins , etal. Determinants of plasma alpha 1-acid glycoprotein (AAG) concentrations in health. Br J Clin Pharmacol. 1985; 20: 500502.

18. S Kishino , A Nomura , S Itoh , etal. Age- and gender-related differences in carbohydrate concentrations of alpha1-acid glycoprotein variants and the effects of glycoforms on their drug-binding capacities. Eur J Clin Pharmacol. 2002; 58: 621628.

19. CH Tuck , S Holleran , L Berglund . Hormonal regulation of lipoprotein(a) levels: effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactant in postmenopausal women. Arterioscler Thromb Vasc Biol. 1997; 17: 18221829.

20. ZH Israili , PG Dayton . Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev. 2001; 33: 161235.

22. K Palmer , P Benfield . Fluvoxamine: an overview of its pharmacological properties and review of its therapeutic potential in nondepressive disorders. CNS Drugs. 1994; 1: 5787.

25. C Kristensen . Imipramine serum protein binding in healthy subjects. Clin Pharmacol Ther. 1983; 34: 689694.

26. K Wilson . Sex-related differences in drug disposition in man. Clin Pharmacokinet. 1984; 9: 189202.

28. B Kalra . Cytochrome P450 enzyme isoforms and their therapeutic implications: an update. Indian J Med Sci. 2007; 61(2): 102116.

29. S Zhou , SY Chan , BC Goh , etal. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005; 44(3): 279304.

31. M Wadelius , E Darj , G Frenne , A Rane . Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther. 1997; 62: 400407.

32. AD Kashuba , AN Nafziger , GL Kearns , etal. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics. 1998; 8: 403410.

33. L Labbe , C Sirois , S Pilote , etal. Effects of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics. 2000; 10: 425438.

34. JS McCune , C Lindley , JL Decker , etal. Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan. J Clin Pharmacol. 2001; 41: 723731.

35. K Brosen . Isoenzyme specific drug oxidation: genetic polymorphism and drug-drug interactions. Nord J Psychiatry. 1993; 47(30): 2126.

36. T Ketter , D Flockhart , R Post , etal. The emerging role of cytochrome P4503A in psychopharmacology. J Clin Psychopharmacol. 1995; 15: 387395.

37. T Edeki , JA Goldstein , SMF de Morais , etal. Genetic polymorphism of S-mephenytoin 4′-hydroxylation in African-Americans. Pharmacogenetics. 1996; 6: 357363.

38. S Sviri , S Shpizen , E Leitersdorf , M Levy , Y Caraco . Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population. Clin Pharmacol Ther. 1999; 65: 275281.

39. DA Price Evans , P Krahn , N Narayanan . The mephenytoin (cytochrome P450 2C 19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos. Pharmacogenetics. 1995; 5: 6472.

40. WJ Tamminga , J Wemer , B Oosterhuis , etal. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol. 1999; 55: 177185.

41. S Hagg , O Spigset , R Dahlqvist . Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol. 2001; 51: 169177.

43. C Scripture , J Pieper . Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet. 2001; 40: 263281.

44. J Ford , C Truman , G Wilcock , etal. Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease. Clin Pharmacol Ther. 1993; 53: 691695.

45. S Hartter , H Wetzel , E Hammes , etal. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology. 1993; 110: 302308.

46. SA Wrighton , JC Stevens . The human hepatic cytochrome P450 involved in drug metabolism. Crit Rev Toxicol. 1992; 22: 112.

48. K Bock , D Schrenk , A Forster , etal. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine and paracetamol as probes. Pharmacogenetics. 1994; 4: 209219.

49. MV Relling , JS Lin , GD Ayers , WE Evans . Racial and gender differences in N acetyltransferase, xanthine oxidase and CYP1A2 activities. Clin Pharmacol Ther. 1992; 52: 643653.

51. JT Callaghan , RF Bergstrom , LR Ptak , CM Beasley . Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999; 37: 177186.

53. JB Schwartz . The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003; 42: 107121.

54. A Karim , M Slater , D Bradford , etal. Oral antidiabetic drugs: bioavailability assessment of fixed-dose combination tablets of pioglitazone and metformin. Effect of body weight, gender, and race on systemic exposures of each drug. J Clin Pharmacol. 2007; 47(1): 3747.

55. Y Lin , GD Anderson , E Kantor , LM Ojemann , AJ Wilensky . Differences in the urinary excretion of 6-beta-hydroxycortisol/cortisol between Asian and Caucasian women. J Clin Pharmacol. 1999; 39: 578582.

56. SE Gaudry , DS Sitar , DD Smyth , JK McKenzie , FY Aoki . Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine. Clin Pharmacol Ther. 1993; 54(1): 2327.

57. UB Berg . Differences in decline in GFR with age between males and females: reference data on clearances of inulin and PAH in potential kidney donors. Nephrol Dial Transplant. 2006; 21(9): 25772582.

60. JS Kim , AN Nafziger . Is it sex or is it gender? Clin Pharmacol Ther. 2000; 68(1): 13.

61. MF Fromm . P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther. 2000; 38(2): 6974.

63. M Jerling , Y Merle , F Mentre , A Mallet . Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. Br J Clin Pharmacol. 1997; 44: 447453.

64. HY Lane , YC Chang , WH Chang , etal. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry. 1999; 60: 3640.

65. M Fabrazzo , G Esposito , R Fusco , M Maj . Effect of treatment duration on plasma levels of clozapine and N-desmethylclozapine in men and women. Psychopharmacology. 1996; 124: 197200.

66. A Rostami-Hodjegan , AM Amin , EP Spencer , etal. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol. 2004; 24: 7078.

67. M Gex-Fabry , AE Balant-Gorgia , LP Balant . Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit. 2003; 25: 4653.

68. DL Kelly , RR Conley , CA Tamminga . Differential olanzapine plasma concentrations by sex in a fixed-dose study. Schizophr Res. 1999; 40: 101104.

69. MV Seeman . Interaction of sex, age, and neuroleptic dose. Compr Psychiatry. 1983; 24: 125128.

70. H Morgenstern , W Glazer . Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medication. Arch Gen Psychiatry. 1993; 50: 723733.

71. R Yassa , D Jeste . Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull. 1992; 18: 701715.

74. K Hatta , T Takahashi , H Nakamura , etal. The association between intravenous haloperidol and prolonged QT interval. J Clin Psychopharmacol. 2001; 21: 257261.

75. A Kuruvilla , J Peedicayil , G Srikrishna , K Kuruvilla , AS Kanagasabapathy . A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol. 1992; 19: 603606.

79. T Baptista , NM Kin , S Beaulieu , EA De Baptista . Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry. 2002; 35: 205219.

80. K Hedenmalm , S Hagg , M Stahl , O Mortimer , O Spigset . Glucose intolerance with atypical antipsychotics. Drug Saf. 2002; 25: 11071116.

81. MJ Sernyak , DL Leslie , RD Alarcon , MF Losonczy , R Rosenheck . Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002; 159: 561566.

83. WR Hutson , RL Roehrkasse , A Wald . Influence of gender and menopause on gastric emptying and motility. Gastroenterology. 1989; 96(1): 1117.

85. DJ Greenblatt , H Friedman , ES Burstein , etal. Trazodone kinetics: effect of age, gender, and obesity. Clin Pharmacol Ther. 1987; 42(2): 193200.

86. JJ Stewart , HJ Berkel , RC Parish , etal. Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J Clin Pharmacol. 2001; 41(7): 770778.

88. DJ Greenblatt , M Divoll , DR Abernethy , RI Shader . Physiologic changes in old age: relation to altered drug disposition. J Am Geriatr Soc. 1982; 30(11): S610.

91. MG Hildebrandt , EW Steyerberg , KB Stage , etal., for the Danish University Antidepressant Group. Are gender differences important for the clinical effects of antidepressants? Am J Psychiatry. 2003; 160: 16431650.

92. E Mundo , R Pirola , L Bellodi , etal. Are gender differences in antiobsessional response related to different clomipramine metabolism? J Clin PsychopharmacoI. 2002; 22: 341342.

93. LC Cohen , J Biederman , TE Wilens , etal. Desipramine clearance in children and adolescents: absence of effect of development and gender. J Am Acad Child Adolesc Psychiatry. 1999; 38: 7985.

95. CA De Mendonca Lima , P Baumann , M Braward-Amey , etal. Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29: 952956.

96. M Reis , MD Chermß , B Carlsson , F Bengtsson , for the Task Force for TDM of Escitalopram in Sweden. Therapeutic drug monitoring of escitalopram in an outpatient setting. Ther Drug Monit. 2007; 29: 758766.

97. RA Ronfeld , LM Tremaine , KD Wilner . Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet. 1997; 32: 2230.

98. JM Ferguson , H Hill . Pharmacokinetics of fluoxetine in elderly men and women. Gerontology. 2006; 52: 4550.

102. SG Kornstein , AF Schatzberg , ME Thase , etal. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry. 2000; 157(9): 14451452.

103. E Baca , M Garcia-Garcia , A Porras-Chavarino . Gender differences in treatment response to sertraline versus imipramine in patients with non-melancholic depressive disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 28(1): 5765.

104. PR Joyce , RT Mulder , SE Luty , etal. Melancholia: definitions, risk factors, personality, neuroendocrine markers and differential antidepressant response. Aust N Z J Psychiatry. 2002; 36(3): 376383.

105. EA Young , SG Kornstein , SM Marcus , etal. Sex differences in response to citalopram: a STAR*D report. J Psychiatr Res. 2009; 43(5): 503511.

106. ME Thase , R Entsuah , M Cantillon , etal. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J Womens Health (Larchmt). 2005; 14(7): 609616.

108. D Marazziti , S Baroni , G Giannaccini , etal. Plasma fluvoxamine levels and OCD symptoms/response in adult patients. Hum Psychopharmacol. 2012; 27(4): 397402.

109. D Marazziti , S Baroni , L Faravelli , etal. Plasma clomipramine levels in adult patients with obsessive-compulsive disorder. Int Clin Psychopharmacol. 2012; 27(1): 5560.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 6
Total number of PDF views: 29 *
Loading metrics...

Abstract views

Total abstract views: 279 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 22nd May 2017. This data will be updated every 24 hours.